Previous 10 | Next 10 |
2024-03-08 11:25:31 ET More on Novo Nordisk Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy Novo Nordi...
2024-03-08 08:00:00 ET Summary Viking Therapeutics' stock initially surged after positive Phase 2 data for its obesity drug, but fell after Novo Nordisk shared data on a new, oral weight loss drug. Eli Lilly and Novo Nordisk have major potential in the obesity market with their dr...
2024-03-07 19:06:31 ET More on Novo Nordisk Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy Biggest st...
2024-03-07 15:11:18 ET More on Viking Therapeutics Viking Therapeutics: VK2735 Data Supports A Buyout Viking Therapeutics: Impressive Obesity Data Puts VK2735 As The Lead Asset (Rating Upgrade) Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Call Transcript ...
2024-03-07 12:05:53 ET Shares of Viking Therapeutics (NASDAQ: VKTX) were plunging 17.4% lower as of 11:52 a.m. ET on Thursday. This decline wasn't caused by an announcement by Viking. Instead, the sell-off appears to be related to Novo Nordisk (NYSE: NVO) reporting results f...
2024-03-07 10:01:04 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-07 08:35:57 ET More on Pre-market losers & stocks. Rail Vision shares rally as Main Line System gets EU approval and certifications Rail Vision wins contract valued at up to $5 million, shares jump Financial information for Airship AI Holdings, Inc. ...
2024-03-06 05:50:00 ET Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (NYSE: LLY) is already giving Novo Nordisk (NYSE: NVO) a run for its money with the approval in the fourth quarter of 2023 of Zepbound. Now another rival co...
2024-03-05 11:16:00 ET The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NYSE:NVO) , thanks to its type 2 diabetes medicine Ozempic and the Wegovy version approved for...
2024-03-05 06:15:00 ET The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite being worth only $2.4 billion in 2022. Where should investors...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-20 06:00:00 ET California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Three Motley Fool contributors think they've found bi...
2024-07-19 05:50:00 ET Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candid...
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO , July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc...